Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)

CNY 18.83

(1.4%)

Market Cap (In CNY)

3.57 Billion

Revenue (In CNY)

1.88 Billion

Net Income (In CNY)

226.67 Million

Avg. Volume

1.18 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
13.741666-23.875
PE
-
EPS
-
Beta Value
0.222
ISIN
CNE100004BD9
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Xiaojuan Deng
Employee Count
-
Website
https://www.lifeonapi.com
Ipo Date
2020-12-15
Details
Hefei Lifeon Pharmaceutical Co., Ltd. engages research, development, production, and sales of pharmaceutical preparations and an active ingredient (APIs). It offers APIs, such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate; medicinal preparations comprising felodipine sustained release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablet, yiqihewei capsule, kunning granule, armillariella oral solution, paeonol ointment, urea and vitamin e cream, Kecuo Yintong gel, and Compound Golden Larch bark gel; and plant extracts, including clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. The company also operates retail chain of pharmaceuticals. Hefei Lifeon Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Hefei, China.